Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

BNC105

Drug

BNC105

Company / Licensee

Bionomics

Market Sector

Oncology

Therapy Class

Vascular disrupting agent and cytotoxic agent (tubulin polymerisation inhibitor)

Product Description

Intravenously administered anti-cancer agent

Development Status

Phase II in progress (Patents granted in the US, Australia and New Zealand)
Expand

Free download worth over $5000
Download our 2019 Technology, Media and Telecoms Predictions Report

Worth up to $5,850

In this report, we look at the 30 big tech themes for 2019, identifying winners and losers for each theme. This report will impact all industries helping:

  • CEOs/Senior Staff: in all industries understand the disruptive threats to their competitive landscape
  • Investors: Helps fund managers focus their time on the most interesting investment opportunities in global TM
Close
Close
Close

Go Top